Autres langues Amplia Therapeutics Limited

Actions

ATX

AU0000023822

Recherche biotechnologique et médicale

Temps Différé Australian S.E. Autres places de cotation 02:19:08 06/08/2026			Varia. 5j.	Varia. 1 janv.
0,1550 ^AUD	0,00%		+19,23%	+3,33%

04/08	Amplia Therapeutics va évaluer une thérapie combinée contre le cancer du poumon non à petites cellules en collaboration avec Eli Lilly ; l'action grimpe de 7 %	MT
04/08	Amplia Therapeutics va évaluer une thérapie combinée contre le cancer du poumon non à petites cellules en collaboration avec Eli Lilly	MT

Autres langues

04/08	Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer
04/08	Amplia Therapeutics to Evaluate Combination Therapy for Non-Small Cell Lung Cancer in Collaboration With Eli Lilly; Shares Rise 7%
04/08	Amplia Therapeutics to Evaluate Combination Therapy for Non-Small Cell Lung Cancer in Collaboration With Eli Lilly
31/07	Amplia Therapeutics Limited Details Preclinical Studies of Narmafotinib In Pancreatic Cancer
31/07	Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online
09/07	Amplia Therapeutics Limited Announces Publication Of New Patent Application For Chemically Novel FAK Inhibitors
09/07	Amplia Announces Publication of New FAK Inhibitor Patent Application
07/07	Amplia Therapeutics Limited Announces Appointment of Brett Carter to Board, Effective July 6, 2026
07/07	Amplia Announces Changes to Board's Leadership Roles
07/07	Amplia Announces Appointment of Brett Carter to Board
06/07	Amplia Therapeutics Limited Announces Board Changes, Effective June 30, 2026
06/07	Amplia Announces Changes to Board’s Leadership Roles
25/06	Amplia Therapeutics Says Washington H. Soul Pattinson Becomes Substantial Holder
24/06	Amplia Therapeutics Says Pengana Capital Becomes Substantial Holder
22/06	Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer
22/06	Amplia Therapeutics Limited Provides Update on Narmafotinib Clinical Progress and Combination Potential with KRAS Inhibitors in Pancreatic Cancer
29/05	Amplia Therapeutics Limited Reports Earnings Results for the Full Year Ended March 31, 2026
29/05	Amplia Therapeutics Limited Auditor Raises 'Going Concern' Doubt
19/05	Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib
19/05	Amplia Therapeutics Limited Initiates Phase 2B Study of Narmafotinib in Pancreatic Cancer
19/05	Amplia Therapeutics to Start Phase 2B Study of Pancreatic Cancer Drug Candidate
11/05	Amplia Therapeutics Shares Up After Entering Agreement to Conduct Ovarian Cancer Clinical Study
09/05	Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
09/05	Amplia Therapeutics Limited And Australia New Zealand Gynaecological Oncology Group Announce Clinical Study Of Narmafotinib In Ovarian Cancer
08/05	Amplia Therapeutics Enters Agreement to Evaluate Lead Drug Candidate in Ovarian Cancer